For example, the sooner the patient was able to be sent home, the sooner the patient was able to return to work, and the sooner, therefore, the patient was contributing to the economy instead of taking from it. This fast-acting treatment also required the fewest number of ancillary services, such as home nursing care. Thus, even though our hypothetical treatment may have been the most expensive treatment available for a given indication, it may have been determined to be the most cost-effective. At that time, one assumed that AIDS was a terminal illness, and many patients with AIDS spent their last days either in a health care facility or at home with some form of palliative care. With newer treatments and newer guidelines for using them, this scenario has become increasingly rare.
Some patients develop viral resistance to some antiretroviral agents.
Other patients exhibit quite the opposite characteristics. Researchers have attempted to quantify these data, and until April 14 and 15, when we hear from Dr. Hillman, we offer the following alphabetical bibliography for your consideration. Major controversies in the DHHS guidelines for use of antiretroviral agents in HIV-infected adults. Department of Health and Human Services. Frank L, Waldron K, Jerrett J, et al.